Charles Schwab Investment Management Inc. Grows Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)
Charles Schwab Investment Management Inc. raised its position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 3.2% in the ...
ENDPOINTS NEWS16h
El­e­va­tion to pay up to $368M in ADC deal; Bavar­i­an Nordic clos­es San Diego site
Columvi combo in DLBCL, while AnaptysBio's ANB032 fails in atopic dermatitis. Essential Pharma gets €1.2B financing deal.
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals
Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.
Stocktwits on MSN19h
AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is Devastated
Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking ...
AnaptysBio price target lowered to $36 from $90 at Guggenheim
Guggenheim lowered the firm’s price target on AnaptysBio (ANAB) to $36 from $90 and keeps a Buy rating on the shares following the announcement ...
AnaptysBio price target lowered to $40 from $56 at Wells Fargo
Wells Fargo analyst Derek Archila lowered the firm’s price target on AnaptysBio (ANAB) to $40 from $56 and keeps an Overweight rating on the ...
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints
AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...